Incyte to acquire Escient Pharmaceuticals for over $750m
The deal includes EP262, a first-in-class, potent, highly selective, once-daily small molecule MRGPRX2 antagonist, and EP547, a first-in-class…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Apr 24
The deal includes EP262, a first-in-class, potent, highly selective, once-daily small molecule MRGPRX2 antagonist, and EP547, a first-in-class…
23 Apr 24
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
03 Apr 24
Under the deal, Genmab will gain global rights to ProfoundBio’s portfolio of next-generation ADCs which consists of three…
26 Mar 24
Cardior is engaged in the discovery and development of therapies that prevent, repair and reverse diseases of the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Mar 24
The acquisition is expected to advance Nuvation Bio as a late-stage, international oncology firm in which its current…
26 Mar 24
Through the deal, the American pharma major gains access to NX-13, Landos Biopharma’s flagship asset, which is being…
22 Mar 24
LENZ Therapeutics to debut on Nasdaq under the ticker symbol “LENZ” as a publicly traded company advancing late…
21 Mar 24
The deal is anticipated to boost Lonza's large-scale biologics manufacturing capacity and will also help the firm cope…
20 Mar 24
IFF’s Pharma Solutions business develops and manufactures pharmaceutical excipients, with around 1100 employees across 10 research and development…
19 Mar 24
The transaction complements AstraZeneca’s oncology portfolio with Fusion’s pipeline of RCs, including its lead programme FPI-2265, and replaces…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates